
City Therapeutics Secures $99.5M Series B for RNAi - Ventureburn
City Therapeutics is a biotechnology company focused on developing RNA interference (RNAi) therapies. Their innovative platform utilizes engineered RNAi trigger molecules to deliver treatments beyond the liver, targeting diseases such as thromboembolic disorders and Stargardt disease. The recent $99.5 million funding will support the advancement of their clinical pipeline.
City Therapeutics Secures $99.5M Series B for RNAi Ventureburn

| Jun 28, 2026 | Delphi Digital | $40.0M | Series B | United States |
| Jun 27, 2026 | Hera | $27.0M | Series A | United States |
| Jun 27, 2026 | Securitize | $400.0M | — | United States |
| Jun 27, 2026 | Generate Biomedicines | $700.0M | Series C | United States |